These findings suggest that combined Hes and ADR treatment exerts a stronger antiproliferative effect than single-agent exposure, implying potential therapeutic benefit through enhanced suppression of ovarian cancer cell growth. This evidence concerns the gene RRBP1 and ovarian cancer.